Erlotinib effective and with fewer side-effects after first-line treatment
A new phase III trial has shown that erlotinib has comparable efficacy to chemotherapy in non-small cell lung cancer patients whose disease has progressed after first-line treatment. The study found no difference in overall survival or progression-free survival time between the two groups.